ReviewImmune network2019
Emerging Themes for the Role of Antibodies in Tuberculosis.
Review in Immune network, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The role of IgA and IgG in Mycobacterium tuberculosis infection: a cross-sectional study in Ethiopia.Clinical and experimental immunology · 2026Article
- Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan.JCI insight · 2023Article
- Antibodies as clinical tools for tuberculosis.Frontiers in immunology · 2023Review
- Mucosal and systemic immune responses after a single intranasal dose of nanoparticle and spore-based subunit vaccines in mice with pre-existing lung mycobacterial immunity.Frontiers in immunology · 2023Article
- The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Coexpression Network Analysis-Based Identification of Critical Genes Differentiating between Latent and Active Tuberculosis.Disease markers · 2022Article
- The knowns and unknowns of latent Mycobacterium tuberculosis infection.The Journal of clinical investigation · 2021Review
- Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection.Cell reports. Medicine · 2021Article
- B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis.Frontiers in immunology · 2021Review
- RNA Sensing ofVaccines · 2020Review
- Mucosal Therapy of Multi-Drug Resistant Tuberculosis With IgA and Interferon-γ.Frontiers in immunology · 2020Article
- Targeting Unconventional Host Components for Vaccination-Induced Protection Against TB.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The best way to debunk a scientific dogma is to throw irrefutable evidence at it. This is especially true if the dogma in question has been nurtured over many decades, as is the case with the apparent redundancy of antibodies (Abs) against intracellular pathogens. Although not fully compelling yet, that 'hard core' evidence is nevertheless now slowly beginning to emerge. This is true for several clinically relevant infections but none more so than
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.